BIIB Oct 2024 245.000 call
| Previous close | 11.60 |
| Open | 11.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 245.00 |
| Expiry date | 2024-10-18 |
| Day's range | 11.60 - 11.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 41 |
GlobeNewswireBiogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational anti-CD38 monoclonal antibody that, through its cell depletion approach, has demonstrated clinical proof of concept in rare immune-mediated indications, with plans to advance to Phase 3Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Bioscience
ZacksWhy Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ZacksIonis (IONS), Biogen Down on Ending Development of ALS Drug
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
